Fatty acid synthase (FASN) is responsible for the endogenous production of fatty acids from acetyl-CoA and malonyl-CoA. Its overexpression is associated with poor prognosis in human cancers including melanomas. Our group has previously shown that the inhibition of FASN with orlistat reduces spontaneous lymphatic metastasis in experimental B16-F10 melanomas, which is a consequence, at least in part, of the reduction of proliferation and induction of apoptosis. Here, we sought to investigate the effects of pharmacological FASN inhibition on lymphatic vessels by using cell culture and mouse models. The effects of FASN inhibitors cerulenin and orlistat on the proliferation, apoptosis, and migration of human lymphatic endothelial cells (HDLEC) were evaluated with in vitro models. The lymphatic outgrowth was evaluated by using a murine ex vivo assay. B16-F10 melanomas and surgical wounds were produced in the ears of C57Bl/6 and Balb-C mice, respectively, and their peripheral lymphatic vessels evaluated by fluorescent microlymphangiography. The secretion of vascular endothelial growth factor C and D (VEGF-C and -D) by melanoma cells was evaluated by ELISA and conditioned media used to study in vitro lymphangiogenesis. Here, we show that cerulenin and orlistat decrease the viability, proliferation, and migration of HDLEC cells. The volume of lymph node metastases from B16-F10 experimental melanomas was reduced by 39% in orlistat-treated animals as well as the expression of VEGF-C in these tissues. In addition, lymphatic vessels from orlistat-treated mice drained more efficiently the injected FITC-dextran. Orlistat and cerulenin reduced VEGF-C secretion and, increase production of VEGF-D by B16-F10 and SK-Mel-25 melanoma cells. Finally, reduced lymphatic cell extensions, were observed following the treatment with conditioned medium from cerulenin-and orlistat-treated B16-F10 cells. Altogether, our results show that FASN inhibitors have anti-metastatic effects by acting on lymphatic endothelium and melanoma cells regardless the increase of lymphatic permeability promoted by orlistat. (2017) 97, 194-206; doi:10.1038/labinvest.2016 published online 5 December 2016 Human fatty acid synthase (FASN, EC2.3.1.85, is the cytosolic enzyme that produces endogenous long-chain fatty acids from acetyl-CoA and malonyl-CoA. 1 Physiologically, FASN is expressed in hormone-sensitive cells and cells with high lipid metabolism, 2 however, in most normal cells, de novo fatty acid synthesis is rarely needed and therefore, FASN levels are usually low. Conversely, several human malignancies as well as some pre-neoplastic lesions show high FASN expression, 3 which suggests its use as a prognostic marker. [4] [5] [6] [7] [8] [9] In fact, FASN was originally identified as the oncogenic antigen-519 (OA-519) in breast cancer patients with poor prognosis. 10, 11 The first experimental evidence of an oncogenic role for FASN came from its overexpression in HBL100 immortalized breast epithelial cells, which show increased proliferation and survival as well as anchorageindependent growth. 12 Similarly, human prostate epithelial cells (iPrECs) overexpressing both FASN and androgen receptor become tumorigenic, suggesting that the former acts as an oncoprotein because of its anti-apoptotic effect. 13 FASN pharmacological inhibitors decrease tumor cell proliferation, elicit tumor cell death, and prevent tumor growth in animal models. 14 Orlistat is a pancreatic lipase inhibitor originally developed as an anti-obesity drug that irreversibly blocks FASN activity and shows anticancer properties. 15 We have
Human fatty acid synthase (FASN, EC2.3.1.85, 270-kDa) is the cytosolic enzyme that produces endogenous long-chain fatty acids from acetyl-CoA and malonyl-CoA. 1 Physiologically, FASN is expressed in hormone-sensitive cells and cells with high lipid metabolism, 2 however, in most normal cells, de novo fatty acid synthesis is rarely needed and therefore, FASN levels are usually low. Conversely, several human malignancies as well as some pre-neoplastic lesions show high FASN expression, 3 which suggests its use as a prognostic marker. [4] [5] [6] [7] [8] [9] In fact, FASN was originally identified as the oncogenic antigen-519 (OA-519) in breast cancer patients with poor prognosis. 10, 11 The first experimental evidence of an oncogenic role for FASN came from its overexpression in HBL100 immortalized breast epithelial cells, which show increased proliferation and survival as well as anchorageindependent growth. 12 Similarly, human prostate epithelial cells (iPrECs) overexpressing both FASN and androgen receptor become tumorigenic, suggesting that the former acts as an oncoprotein because of its anti-apoptotic effect. 13 FASN pharmacological inhibitors decrease tumor cell proliferation, elicit tumor cell death, and prevent tumor growth in animal models. 14 Orlistat is a pancreatic lipase inhibitor originally developed as an anti-obesity drug that irreversibly blocks FASN activity and shows anticancer properties. 15 We have previously shown that FASN inhibition with orlistat significantly reduces the number of spontaneous mediastinal lymph node metastasis from intraperitoneal B16-F10 mouse melanomas. 16 However, we have also demonstrated that orlistat reduces the proliferation and promotes apoptosis through activation of the intrinsic pathway in the same cells, independent of p53 or mitochondrial permeability transition. 16, 17 Furthermore, FASN inhibition with orlistat reduces both the proliferation of human blood vessel endothelial cells and neovascularization in an ex vivo assay, suggesting antiangiogenic abilities for this drug. 18 Lymphatic vessels regulate tissue fluid homeostasis, immune cell trafficking, and the absorption of dietary fats. 19, 20 In adult tissues, lymphangiogenesis is observed during wound healing, tumor growth, and metastasis. 21 Lymphatic circulation is the main route for metastasis in several malignancies, such as those from breast, pancreas, stomach, colon, head and neck, prostate, lung, and melanomas. 22, 23 Vascular endothelial growth factor (VEGF) family members and its receptors have a central role in angiogenesis and lymphangiogenesis in both physiological and pathological conditions. 24 VEGF-C and -D have major roles in tumor lymphangiogenesis 25, 26 through the interaction with vascular endothelial growth factor receptor (VEGFR)-3 and VEGFR-2 (mainly associated with angiogenesis). 27 In addition, co-receptors such as neuropilin-2 (NRP--2), post-translational cleavage of VEGF-C and -D, as well as VEGFR-2/VEGFR-3 heterodimerization are also involved in this process. [27] [28] [29] In mouse models, VEGF-C and -D overexpression is associated with increased lymphatic vessel density and lymph node metastasis in different types of cancer. [30] [31] [32] [33] [34] Both factors were detected in several human malignancies, such as melanomas, adenocarcinomas of the lung, as well as breast, colon, head and neck, and gastric cancers. 22 However, the expression of VEGF-C, but not VEGF-D, has been correlated with lymph node metastasis in different types of cancers, including melanoma. 27, [34] [35] [36] Lymph node metastases are important for tumor staging and therapeutic decisions, and the density of tumor-associated lymphatic vessels seems to correlate with the incidence of lymph node metastasis and poor prognosis in melanoma and other human malignancies. 21, 22, 37, 38 Moreover, the number and size of intratumoral lymphatic vessels is significantly higher in metastatic melanomas and correlated with poor disease-free and overall survival. 39 The role of FASN on the lymphatic network and tumor-induced lymphangiogenesis is still unknown. Here, we provide the first evidence that FASN inhibitors differentially modulate VEGF-C and -D expression in mouse melanoma cells and act both on lymphatic endothelial cells and melanoma cells. We also demonstrate that orlistat affects the permeability of the lymphatic vasculature and reduces the size of lymph node metastasis in experimental melanomas. Cell Culture  B16-F10 mouse melanoma cells and SK-Mel-25 human  melanoma cells (ATCC, Manassas, VA, USA) were maintained in RPMI (Invitrogen, Camarillo, CA, USA) with 1 or 10% of fetal bovine serum (FBS, Cultilab, Campinas, Brazil). Human oral squamous carcinoma cells (SCC-9, ATCC) were grown in DMEM/F-12 (Invitrogen) with 10% FBS and 400 ng/ml hydrocortisone. hTERT-HDLEC human lymphatic endothelial cells 40 were cultured in Endothelial Basal Medium-2 (EBM-2, Lonza, Walkersville, MD, USA) supplemented with single quots (Lonza), 5% of FBS, and 1:500 penicillin-streptomycin (Invitrogen). Primary human dermal lymphatic endothelial cells (HDLEC, Promocell, Heidelberg, Germany) were cultured in endothelial cell growth medium MV2 (Promocell). Cells were cultured with or without antibiotic/antimycotic solution (Invitrogen) at 37°C in humidified atmosphere with 5% CO 2 . Orlistat (Roche, Basel, Switzerland) was prepared as described elsewhere 41 and cerulenin (Sigma-Aldrich, St Louis, MO, USA) used at the concentrations described in the figure legends.
MATERIALS AND METHODS
Cell Viability, Proliferation, and Apoptosis Cell viability was determined by seeding 2 × 10 5 HDLEC cells in 6-well culture plates with 3(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT, Sigma) according to the manufacturer's instructions. For the study of cell cycle and apoptosis, HDLEC cells (4 × 10 5 ) were seeded in T-25 culture flasks and serum starved for 24 h (cell cycle only). The medium was replaced by fresh medium containing FASN inhibitors and HDLEC cells incubated for additional 24 h, collected and cell cycle or apoptosis analyzed as previously described. 17 All experiments were performed at least three times independently.
Spheroid Assay
The in vitro lymphangiogenesis assay with spheroids was performed as described by Detry et al. 42 Spheroids were generated by seeding 2 × 10 3 hTERT-HDLEC cells in each well of 96-well non-adherent culture plates with round bottom (Greiner, Frickenhausen, Germany) in reduced EBM-2 medium (without growth factors) containing 1% of FBS and 0.24% of high viscosity methylcellulose (Sigma). After 24 h at 37°C and 5% CO 2 , cells from each well formed spheroids that were collected and embedded into 600 μl of collagen gels. Type I collagen from rat tail (BD Biosciences, San Jose, CA, USA) was prepared according to the manufacturer and mixed 1:1 with 1.2% methylcellulose dissolved in reduced medium. Spheroids were then seeded in 24 well plates and incubated at 37°C in 5% CO 2 . FASN inhibitors were added in both collagen gels and cell culture media. Conditioned medium obtained from B16-F10 cells treated or not with cerulenin or orlistat was also used to incubate the spheroids. After 24 h, the spheroid sprouting/ migration was visualized and photographed in a phase-contrast microscope (Leica Microsystems, Wetzlar, Germany). The number of cells that migrate from each spheroid and the filopodia-like cell extensions were counted with the aid of the Scion Image software (Scion Corporation, Frederick, MD, USA).
Lymphatic Ring Assay
Tridimensional primary cultures of mouse lymphatic endothelial cells were performed according to Bruyère et al. 43 Thoracic ducts were removed from female C57Bl/6 mice with 4-8 weeks of age by microsurgery and cut into 1 mm pieces. The explants were embedded between two layers of type I collagen (2 mg/ml, Serva Electrophoresis, Heidelberg, Germany) and cultured for 11 days in MCDB-131 (Invitrogen) supplemented with 4% Ultroser G (BioSepra, Northborough, MA, USA), 25 mM of NaHCO 3 , 1% of glutamine, 100 U/ml of penicillin, and 100 mg/ml of streptomycin. Cultures were maintained at 37°C in a humidified incubator (HERAcell 150, Heraeus, Hanau, Germany) under reduced oxygen condition (5% O 2 , 5% CO 2 , and 90% N 2 ). The rings were photographed each 2 days and the image analyses performed at day 10. On day 11, lymphatic rings were collected, washed for 30 min in PBS, fixed for 30 min with 70% ethanol and used for alpha smooth muscle actin (α-SMA) whole mount immunostaining. Rings negative for α-SMA were used for quantification, which was performed by generating a grid of concentric circles by successive increments at fixed intervals from the thoracic duct boundary. The number of microvessel-grid intersections was counted and plotted according to the distance from the ring. At least five images for each experimental condition were used and the values obtained from 0.15 to 0.75 mm in the control and treated explants compared. All experiments were approved by the Committee for Ethics in Animal Research of the State University of Campinas (1934-1).
Protein Extraction and Western Blotting
Protein lysates from cells or experimental melanomas and western blotting reactions were done as previously described 16 with antibodies against FASN (Transduction Laboratories, Lexington, KY, USA) diluted at 1:3000. Antibodies against β-actin (Sigma, 1:30 000) were used as the loading control.
Immunofluorescence for VEGFR-3
Orlistat-or cerulenin-treated HDLEC cells were stained with anti-VEGFR-3 antibodies (Reliatech). HDLEC cells (1 × 10 6 ) were seeded in 150 mm culture dishes and after 24 h treated with orlistat or cerulenin for additional 24 h. Then, cells were collected by scraping with cell-spatulas in cold PBS. The cell suspension was fixed in 70% ETOH for 15 min, washed with PBS, blocked with 1% PBS/BSA, and incubated with antibodies against VEGFR-3 (1:100) for 1 h at room temperature. After another washing step, cells were incubated with FITC-anti-rat antibodies (1:250, Vector Laboratories, Burlingame, CA, USA) for 1 h and, after further washing, cell suspensions analyzed in a FACSCalibur flow cytometer equipped with an argon laser and CellQuest software (Becton Dickinson, Bedford, MA).
Animal Experiments and Microlymphangiography
The animal studies were approved by the Committee for Ethics in Animal Research of the State University of Campinas (1333-1). For the hole punch assay, Balb-C mice were anesthetized with ketamine/xylazine (10/100 mg/kg i.p.) and a hole (1.5 mm of diameter) made in the center of both ears by using a metal ear punch. The animals were treated for 25 days with i.p. injections of orlistat (Roche, 240 mg/kg) or the equivalent amount of vehicle (33% ethanol in PBS) according to Kridel et al 15 and killed by cervical dislocation. For the analysis of peritumoral lymphatics, primary tumors, and lymph node metastases, 10 5 B16-F10 cells resuspended in 5 μl of PBS were injected intradermally in each ear of C57Bl/6 mice with 5-8 weeks of age. C57Bl/6 mice without surgical wounds or melanomas were also treated and killed as described above. The number of animals and experimental groups is shown in Supplementary Table 1. Functional lymphatics were visualized as described elsewhere, 44 after the injection of 2 μl of lysine-fixable FITC-dextran (2000 kDa, Molecular Probes, Eugene, OR, USA). Photomicrographies were performed in a Leica DMR microscope with epifluorescence (Leica Microsystems) and images with identical conditions of light, contrast, and magnification used for the analysis with the Scion Image software (Scion Corporation). The lines drawn along the lymphatic trajectory were measured in pixels and converted in millimeters according to the image size. Metastatic superficial cervical lymph nodes were blackened and therefore easily detected and collected. Previous studies demonstrated that Evan's blue or fluorescence auricular lymphangiography revealed a dense auricular network of lymphatic capillaries, draining to a larger vessel at the ear base and subsequently to the superficial cervical lymph nodes. 44 The volumes of the primary tumors and metastatic lymph nodes were calculated by using the formula volume = width 2 (mm) × length (mm)/2. Samples of the primary tumors, lymph nodes, and livers were collected and immediately frozen in liquid nitrogen for total RNA and protein extractions or Oil red O staining. 45 Experiments were made three times independently.
Quantitative RT-PCR Total RNA was extracted from tumor tissues or cell pellets using the Trizol reagent (Invitrogen) according to the manufacturer's instructions. RNA samples were treated with 1 U of DNAse I (amplification grade, Invitrogen) for 10 min at room temperature to eliminate genomic DNA contamination. cDNAs were synthesized from 1 to 3 μg of total RNA using the First-Strand cDNA Synthesis SuperScripT II RT (Invitrogen). Quantitative RT-PCR was conducted using SYBR Green Real-time PCR Master Mix (Applied Biosystems, Warrington, UK). The cycling conditions were 95°C for 10 min, and 40 cycles of 95°C for 15 s and 57°C for 1 min in a StepOne Plus Real-Time PCR System (Applied Biosystems). Primer sequences are listed in Supplementary Table 2 and the relative gene expression determined by the 2 − ΔΔ CT or standard curve methods with the aid of the SDS software version 2.0.
Conditioned Media and ELISA Conditioned media were obtained by seeding 3 × 10 5 B16-F10 cells in 100 mm culture dishes with complete growth medium. After 24 h, medium was changed by fresh medium containing 50, 100, or 300 μM of orlistat supplemented with 1% FBS, which was collected after additional 24 h. Cells and 
siRNA-Silencing of FASN Expression
The 25-mer RNA molecules were synthesized, annealed, and purified by the manufacturer (Stealth RNAi, Invitrogen). The following sequences targeting Mus musculus FASN (NM_00798) were used: 5′-CAA TGA TGG CCA ACC GGC TCT CTT T 3′), 5′-TGG GAA GAC CCG AAC TCC AAG TTA T-3′, and 5′-CCT CTG GGC ATG GCT ATC TTC TTG A-3′. B16-F10 cells grown to 50% confluence were transfected with 200 nM of a mixture containing equal parts of specific siRNAs using a liposome method according to manufacturer's instructions (Lipofectamine 2000, 3 μl/ml, Invitrogen). As negative controls, cells were transfected with equimolar concentrations of a nonspecific control oligo (Figures 1f and g ). These results show that primary cultures of lymphatic endothelial cells actively synthesize FASN and are sensitive to FASN inhibitors.
FASN Inhibitors Decrease Migration of Lymphatic Endothelial Cells and Lymphatic Outgrowth
To better understand the effects of FASN inhibitors on the lymphatic vasculature, we next tested the impact of cerulenin or orlistat on hTERT-HDLEC cells in the spheroid migration assay. These studies show that all tested concentrations of these drugs (Figures 2a-f ) reduced lymphatic endothelial cell migration, which was assessed by counting the number of cells isolated from the spheroids after 24 h (Figures 2g and h ). The treatment with 2 or 2.5 μg/ml of cerulenin and 100 or 300 μM of orlistat also reduced lymphatic endothelial cell outgrowth from cultured explants of mice lymphatic ducts when compared with their respective vehicles (Figures 3a-f) . The outgrowth of lymphatic cells in the DMSO controls reached the maximal distance of 1.15 mm, which was reduced by 35% in the cerulenin-treated explants (Figures 3g and h) . Similarly, the maximum distance reached by lymphatic cells in ETOH was 1 mm and did not exceed 0.7 mm (30% of reduction) in the presence of orlistat (Figure 3i ).
FASN Inhibitors Differentially Modulate VEGF-C and -D in Melanoma Cells
To verify a role for FASN inhibitors on the melanomainduced lymphangiogenesis, we next analyzed the production of VEGF-C and -D in cultured B16-F10 and SK-Mel-25 cells treated with cerulenin or orlistat. Enhanced secretion of VEGF-D by cerulenin-and orlistat-treated B16-F10 cells was verified by ELISA, which was further confirmed by the FASN knockdown with specific siRNAs (Figures 4a-d) . Both drugs stimulated the secretion of VEGF-D and reduced the production of VEGF-C in SK-Mel-25 cells (Figures 4e-h ). In addition, the immunopositivity for VEGFR-3 was significantly reduced in HDLEC cells treated with cerulenin or orlistat (Figures 4i and j) .
Orlistat Reduces the Size of Lymph Node Metastases and its VEGF-C Expression
Once intradermally injected in the C57Bl/6 mice ears, B16-F10 cells develop primary tumors and lymph node metastases in approximately one week and 20 days, respectively (Figures 5a and b) . The most frequent pattern of metastatic spread was bilaterally to the lateral superficial cervical lymph nodes (Figure 5b) , although unilateral lymph node metastasis were also found. Importantly, the lateral superficial cervical lymph node metastases from the orlistat-treated mice were 39.25% smaller than the metastases found in the control animals (Po0.05, Student's t-test) (Figure 5c ). The volumes of primary tumors were calculated and no differences between the control and orlistat-treated groups were detected (data not shown). Histologically, the primary tumors from the two experimental groups were indistinguishable and characterized by malignant melanocytes with hyperchromatic nuclei, multiple nucleoli, cytoplasmic melanin accumulation, and atypical mitoses, generally adjacent to the ear cartilage (Figure 5d ). The lymph node metastases were microscopically confirmed and characterized by the peripheral infiltration of B16-F10 cells (Figure 5e ). As depicted in Figures 5f and g, the effectiveness of systemic FASN inhibition with orlistat was demonstrated by the observation of Oil red O stained liver frozen sections, in which the hepatocytes from control mice were rich in large lipid droplets, in contrast with the weakly stained cells from the orlistat-treated group. Interestingly, the intensity of FASN protein bands were increased in lysates from primary tumors of orlistat-treated mice, in comparison with the control mice, possibly as a feedback response (Supplementary Figures S1a and b) . As depicted in Figures 5h and i , orlistat did not affect the expression of VEGF-D, but decreased VEGF-C levels in experimental lymph node metastasis. Interestingly, the transcripts for both growth factors in the primary tumors were not affected by this drug (data not shown). Despite the well characterized anti-obesity properties of orlistat, the body weight of treated mice was not affected.
Orlistat Enhances Lymphatic Staining by FITC-Dextran In vivo
To check whether the treatment with orlistat affects the lymphatic vasculature, we first examined the lymphatic network at the periphery of surgical wounds performed in Balb-C mice ears. Twenty five days after the beginning of the treatment with orlistat, fluorescent dextran microlymphangiographies revealed more positive lymphatic vessels in treated than in control mice (Figures 6a and b) . Similar observations were made in B16-F10 peritumoral lymphatics, which after the treatment with orlistat were denser than the controls (Figures 6d and e) . Although in a lesser extent, the lymphatic vessel density was also higher in the ears of orlistattreated mice without surgical wounds or experimental melanomas, suggesting that the drug systemically changes lymphatic vessel architecture and/or permeability (Figures 6g  and h ). The quantitative analysis of lymphatic vessel densities confirmed the higher lymphatic density in the orlistat-treated mice from the three experimental models (Figures 6c, f and i) . These animals showed no significant physical or behavioral alterations during the period of treatment.
Conditioned Medium from B16-F10 Cells Treated with Cerulenin or Orlistat Reduce the Filopodia-Like Cell Extensions of Cultured Lymphatic Endothelial Cells
To better understand the effects of FASN inhibitors on the lymphatic vasculature, we next used conditioned medium from mouse melanoma cells to incubate hTERT-HDLEC cells in the spheroid assay. Conditioned medium from cerulenin- (Figures 7b and e) or orlistat-treated (Figures 7d and f) B16-F10 cells did not affect lymphatic endothelial cell migration in comparison with the respective controls (Figures 7a and c) . However, the number of cells without filopodia-like extensions was significantly higher in the presence of cerulenin or orlistat and the number of cells with three or more of these structures was higher in the controls (Figures 7g and h ).
DISCUSSION
The association between FASN expression and activity with tumor growth, metastasis, and prognosis has been Figure 3 Cerulenin and orlistat inhibit the lymphatic capillary growth in the lymphatic ring assay. The treatment with 2 (b) or 2.5 μg/ml (c) of cerulenin promoted an anti-lymphangiogenic effect on the explants from mice lymphatic ducts when compared with the DMSO controls (a). Orlistat also reduced capillary formation at 100 (e) in comparison with the ETOH controls (d). The capillary growth was strongly affected by 300 μM of orlistat (f). The growth of lymphatic structures in the DMSO controls (■) reached the maximal distance of 1.15 mm, whereas the treatment with 2 or 2.5 μg/ml of cerulenin (■) reduced this distance to 0.75 mm (35%) (g and h). The higher distance reached by lymphatic structures in ETOH (■) was 1 mm, which did not exceed 0.7 mm (i) in presence of 100 μM of orlistat (■). Two independent experiments were evaluated (explants per condition: DMSO n = 15; 2 and 2.5 μg/ml n = 12; ETOH n = 14; 100 μM n = 10). *Po0.05, Student's t-test. Scale bars, 500 μm (a-f). Error bars indicates mean ± s.d. of at least three independent experiments. demonstrated in several types of human malignancies. 3 In fact, fatty acid biosynthesis within tumor tissues occurs at high rates regardless nutritional supply, 46, 47 and FASN blockage or knockdown inhibits proliferation and promotes apoptosis in cultured cancer cell lines. 13, [15] [16] [17] [48] [49] [50] It is generally accepted that normal human tissues preferentially use dietary fat for the synthesis of new structural lipids and the de novo fatty acid synthesis is maintained at low levels. 11, 51 Herein, we show that FASN is critical for both proliferation and survival of HDLEC cells, as cerulenin and orlistat significantly reduced their growth, viability, and induced apoptosis. However, the mechanisms by which FASN inhibition affects these processes in malignant and nonmalignant cells remain to be elucidated. We also show in the present study that these drugs inhibit HDLEC lateral migration in the spheroid assay and decrease the growth of murine lymphatic capillaries in the ex vivo model providing the first evidence of their anti-lymphangiogenic activity. These findings are in agreement with those from Browne et al, 18 which showed that pharmacological inhibition of FASN with orlistat decreases ex vivo human neovascularization. Recent studies from our group demonstrate that orlistat reduces the viability and proliferation of rabbit aortic endothelial cells as well as impairs the development of capillary-like structures by the same cells in Matrigel. 51 Therefore, the results here presented corroborate the growing body of evidence indicating that FASN is also needed for the growth and maintenance of nonmalignant cells. 18, 51, 52 VEGF family members orchestrate both angiogenic and lymphangiogenic processes in physiological and pathological conditions. VEGF-A, -B, -E, -F, and PIGF act in angiogenesis and vasculogenesis, whereas full-length VEGF-C and -D preferentially bind to VEGFR-3 to promote lymphangiogenesis. 25, 26 Although elevated levels of both VEGF-C and -D are associated with increased lymphangiogenesis and metastasis in mouse tumor models, [30] [31] [32] [33] [34] studies with clinical samples have suggested a role for VEGF-C, but not VEGF-D, in metastatic spread and prognosis. 27 In fact, elevated VEGF-C levels seems to correlate with lymph node metastasis in a variety of human cancers such as breast, colon, rectum, prostate, esophagus, stomach, lung, uterine cervix, endometrium, and melanomas, 53, 54 in which VEGF-C production is high in the vertical phase of growth. 35, 55 Conversely, the role of VEGF-D in lymph node metastasis in melanomas remains unclear. 35 Our results show increased VEGF-D and reduced VEGF-C in B16-F10 and SK-Mel-25 cells treated with both cerulenin and orlistat. In addition, HDLEC cell proliferation was significantly inhibited by conditioned media from cerulenin-or orlistat-treated SKMel-25 cells (data not shown), further suggesting that FASN inhibitors produce an anti-lymphangiogenic phenotype in melanoma cells. Interestingly, the treatment with orlistat did not affect VEGF-D expression in our primary melanomas and their metastases; however, decreased VEGF-C mRNAs were found in the latter. We speculate that VEGF-D changes in primary tumors were not detected because of their complex microenviroment, which may mask the drug effects.
FASN role on lymphatic cells
Previous results from our group show that orlistat reduces experimental melanoma 16 and oral squamous cell carcinoma metastasis, 56 and that FASN may have a role in tumor angiogenesis. 51 In fact, Seguin et al 51 showed reduced formation of HUVEC capillary-like structures in culture medium previously conditioned by orlistat-treated SK-Mel-25 cells because of the enhanced production of the inhibitory isoform VEGF-A 165b by melanoma cells. In agreement with these results, Zaytseva et al 57 demonstrated that the knockdown of FASN resulted in downregulation of VEGF 189 and upregulation VEGF 165b in colorectal cancer cell lines. In addition, Menendez et al 58 demonstrated that FASN inhibition with C75 increases the production of total VEGF-A and accumulates HIF-1α in breast cancer cells, suggesting a hypoxia-like response. Accordingly, here we show that the size of lymph node metastases from experimental cutaneous melanomas is significantly reduced by the treatment with orlistat. As in our previous study with B16-F10 tumors, 16 orlistat did not affect primary tumor size, which can be explained by their rapid growth and aggressiveness at the time of their metastatic spread. Despite the relevant results obtained in vitro, the use of cerulenin in vivo is limited because of its chemical instability. 58 The association between FASN inhibitiors and production of lymphangiogenic growth factors by cancer cells has not yet been described. However, hypoxia enhances VEGF-D and VEGFR-3 mRNAs in vein endothelial cells and regulates VEGF-D activity in smooth muscle cells. 59, 60 Hypoxia is also associated with lymphangiogenesis, lymphatic differentiation, and VEGF-A, VEGF-C, and VEGF-D expression in cervical cancer cells. 61 Moreover, VEGF-D expression is associated with HIF-1α in breast cancer tissues. 62 Recently, Sounni et al 63 showed that the inhibition of the de novo lipogenesis with orlistat in human and mouse breast, colon and lung FASN role on lymphatic cells DC Bastos et al models reduces tumor regrowth after the treatment with antiangiogenic therapy with sunitinib or sorafenib suggesting a link between therapeutic resistance to these drugs and lipid metabolism. Nevertheless, the lymphatic endothelial growth inhibition and induction of apoptosis observed in our in vitro studies did not reflect the results from the animal models, where orlistat-treated mice showed increased lymphatic permeability. We speculate that the decreased lymphatic endothelial cell extensions observed after incubation with conditioned medium from orlistat-or cerulenin-treated melanoma cells enhances lymphatic vessel permeability. In addition, filopodial outgrowth depends on actin polymerization at the glycerophospholipid PtdIns (4,5)P 2 and (3,4,5)P 3 , composed by fatty acids with 16-20 carbon molecules, that are critical for the membrane-cytoskeleton interactions via activation of the PI3K pathway. 64, 65 In fact, FASN pharmacological inhibition reduces the synthesis of phospholipids incorporated into lipids rafts, detergent-resistant microdomains, which act as platforms for signal transduction, including via PI3K. 66 Despite the fact that the involvement of FASN in filopodia outgrowth is largely unknown, our results suggest that FASN inhibitors may change lymphatic endothelial cell-to-cell or cell-to-matrix contacts and perhaps increase lymphatic permeability.
In summary, the present study shows that orlistat reduces the size of lymph node metastasis from experimental 
